Palavras-chave
Dor crônica
Maconha medicinal
Como Citar
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Resumo
Objetivo: Analisar as evidências disponíveis na literatura científica sobre os efeitos do canabidiol (CBD) na redução da dor e na melhora da qualidade de vida de pacientes adultos com dor crônica. Métodos: Trata-se de uma revisão integrativa da literatura realizada através das bases PubMED, Biblioteca Virtual em Saúde (BVS) e Periódico CAPES, usando os descritores: “Cannabidiol”, “Chronic Pain” e “Adults”, e obtendo o truncamento de pesquisa: (Cannabidiol) AND (Chronic Pain) AND (Adults). Foram encontrados 343 artigos, filtrados conforme critérios de inclusão (idiomas português, inglês e espanhol; período de 2020 a 2025; artigos completos) e exclusão (artigos duplicados, resumos, fora do escopo). Resultados: O canabidiol (CBD) é um composto derivado da cannabis que vem sendo estudado como alternativa terapêutica no tratamento da dor crônica em adultos, mostrando efeitos analgésicos, melhora na qualidade de vida e potencial redução no uso de opióides. Considerações finais: O canabidiol (CBD) demonstra efeitos positivos no controle da dor crônica em adultos, com redução do uso de opióides e baixa incidência de efeitos adversos, embora ainda sejam necessários estudos mais consistentes para confirmar sua eficácia e segurança.
Referências
ABRAMS DI, et al. Effect of inhaled cannabis for pain in adults with sickle cell disease: A randomized clinical trial: A randomized clinical trial. JAMA network open, 2020; 3(7): e2010874.
ARAGONA F, et al. Role of cannabidiolic acid or the combination of cannabigerol/cannabidiol in pain modulation and welfare improvement in horses with chronic osteoarthritis. Frontiers in veterinary science, 2024; 11: e1496473.
BAWA Z, et al. An open-label feasibility trial of transdermal cannabidiol for hand osteoarthritis. Scientific reports, 2024; 14(1): 11792.
BERGMANS RS, et al. Protocol for a pragmatic trial of Cannabidiol (CBD) to improve chronic pain symptoms among United States Veterans. BMC complementary medicine and therapies, 2024; 24(1): 250.
BRAZEAU D, et al. Impact of an acute 1-month cannabidiol treatment on pain and inflammation after a long bone fracture: a triple-blind randomized, placebo-controlled, clinical trial protocol. BMJ open, 2025; 15(2): e092919.
BOEHNKE KF, et al. Cannabidiol product dosing and decision-making in a national survey of individuals with fibromyalgia. The journal of pain: official journal of the American Pain Society, 2022; 23(1): 45–54.
CUNNINGHAM CO, et al. Medical Marijuana and Opioids (MEMO) Study: protocol of a longitudinal cohort study to examine if medical cannabis reduces opioid use among adults with chronic pain. BMJ open, 2020; 10(12): e043400.
GIANGREGORIO A, et al. Predictors of response to medical cannabis for chronic pain: A retrospective review of real-time observational data. Cannabis (Research Society on Marijuana), 2024; 7(3): 167–176.
HALL N, et al. Topical cannabidiol is well tolerated in individuals with a history of elite physical performance and chronic lower extremity pain. Journal of cannabis research, 2023; 5(1): 11.
HOCH E, et al. Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits. European archives of psychiatry and clinical neuroscience, 2025; 275(2): 281–292.
HUANG A, et al. A survey on the use of cannabidiol (CBD) isolate, its perceived benefits, and associated side effects among subjects with chronic pain. Cureus, 2025; 17(3): e80198.
KAUFMANN R, et al. Long-term, self-dosing CBD users: Indications, dosage, and self-perceptions on general health/symptoms and drug use. Medical cannabis and cannabinoids, 2023; 6(1): 77–88.
LENT MR, et al. Clinical and psychosocial changes in adults with opioid use disorder and chronic pain using medical cannabis: a brief report. Journal of cannabis research, 2025; 7(1): 36.
MANCA A, et al. Cannabinoid levels description in a cohort of patients with chronic and neuropathic pain treated with Cannabis decoction: A possible role of TDM. Biomedecine & pharmacotherapie, 2024; 175(116686): 116686.
MORENO-SANZ G, et al. Sex-dependent prescription patterns and clinical outcomes associated with the use of two oral cannabis formulations in the multimodal management of chronic pain patients in Colombia. Frontiers in pain research (Lausanne, Switzerland), 2022; 3: e854795.
NUTT DJ, et al. A multicriteria decision analysis comparing pharmacotherapy for chronic neuropathic pain, including cannabinoids and cannabis-based medical products. Cannabis and cannabinoid research, 2022; 7(4): 482–500.
PIKE CK, et al. Study protocol for a phase II, double-blind, randomized controlled trial of cannabidiol (CBD) compared with placebo for reduction of brain neuroinflammation in adults with chronic low back pain. BMJ open, 2022; 12(9): e063613.
PRAMHAS S, et al. Oral cannabidiol (CBD) as add-on to paracetamol for painful chronic osteoarthritis of the knee: a randomized, double-blind, placebo-controlled clinical trial. The Lancet regional health. Europe, 2023; 35(100777): 100777.
PUD D, et al. Cannabis oil extracts for chronic pain: what else can be learned from another structured prospective cohort? Pain reports (Baltimore, Md.), 2024; 9(2): e1143.
SOLMI M, et al. Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomized controlled trials and observational studies. BMJ (Clinical research ed.), 2023; 382: e072348.
VILLANUEVA MRB, et al. Efficacy, safety, and regulation of cannabidiol on chronic pain: A Systematic Review. Cureus, 2022; 14(7): e26913.
WILLIAMS AR, et al. Adult medical cannabinoid use and changes in prescription controlled substance use. Cannabis and cannabinoid research, 2023; 8(5): 933–941.